9 results about "Thrombopoietin" patented technology

A hematopoietic stem cell (HSC) proliferation medium includes a basal medium, 0.1 ng / mL to 200.0 ng / mL of thrombopoietin (TPO), 0.1 ng / mL to 200.0 ng / mL of stem cell factor (SCF), 0.1 ng / mL to 20.0 ng / mL of interleukin-3 (IL-3), 0.1 ng / mL to 100.0 ng / mL of interleukin-6 (IL-6), 0.1 ng / mL to 200.0 ng / mL of Flt-3 ligand (FL), 0.1 μg / mL to 20.0 μg / mL of insulin, 0.1 μg / mL to 120.0 μg / mL of transferrin, 0.1 g / L to 3.0 g / L of human serum albumin (HSA), 0.1 μM to 4.0 μM of pyrimido-indole derivative UM729, and 0.1 μM to 2.0 μM of aryl hydrocarbon receptor (AhR) antagonist StemRegenin 1 (SR1). Methods for in vitro proliferation of hematopoietic stem cells (HSCs) and in vitro production of hematopoietic progenitor cells (HPCs) using the HSC proliferation medium are also provided.

The invention discloses a freeze-dried preparation of a pegylated thrombopoietic peptide as well as a preparation method and application of the freeze-dried preparation. The freeze-dried preparation comprises the pegylated thrombopoietic peptide, histidine, glycine, mannitol and cane sugar. The preparation method of the pegylated thrombopoietic peptide comprises the following steps: carrying out coupling treatment on the thrombopoietic peptide and polyethylene glycol to obtain the pegylated thrombopoietic peptide, the thrombopoiesis promoting peptide is prepared from fusion protein; the amino acid sequence of the fusion protein is shown as Xm-(Y-Z) n, X is an insulin glargine mutant, Y is a restriction enzyme cutting site, Z is a thrombopoiesis promoting peptide, m is 1 or 2, and n is 1 or 2. The fusion protein is efficiently expressed in a thallus in the form of an inclusion body, the expressed fusion protein is cut by adopting specific protease, the thrombopoiesis promoting peptide is released, the integrity of the thrombopoiesis promoting peptide can be ensured, and the cutting efficiency is high. The pegylated thrombopoiesis promoting peptide and the preparation thereof can effectively treat and prevent tumor drug related thrombocytopenia, primary immune thrombocytopenia, chronic liver disease related thrombocytopenia and acute radiation syndrome hematopoietic syndrome.

The invention provides a virus vector for hematopoietic stem cells and application of the virus vector. The first aspect of the application provides a lentiviral vector packaging system for hematopoietic stem cells, the lentiviral vector packaging system comprises a recombinant expression vector, and the recombinant expression vector comprises nucleotide sequences encoding thrombopoietin and a fms associated receptor tyrosine kinase 3 ligand. The thrombopoietin and the fms related receptor tyrosine kinase 3 ligand are constructed on the nucleic acid molecule, so that the thrombopoietin and the fms related receptor tyrosine kinase 3 ligand are expressed on the surface of a lentiviral vector and the like; the stemness or immunocompetence of various cells including hematopoietic stem cells can be effectively activated and improved under the condition of lower dosage.

The invention discloses a pharmaceutical composition for treating and curing acute radiation sickness, which comprises idebegrasbine alpha and a thrombopoiesis promoting drug (ropursbine or rhTPO), according to the application disclosed by the invention, for the first time, the fact that the combination of the idebesisterone alpha and the thrombopoiesis promoting drug (ropsisterone or rhTPO) has a remarkable synergistic effect on the treatment of the acute radiation sickness is found, and an effective drug combination strategy is provided for the treatment of the acute radiation sickness; the compound has a wide application prospect in the technical field of development of acute radiation sickness prevention and treatment medicines.

The invention belongs to the technical field of biological genetic engineering, and particularly relates to a canine TPO recombinant protein, a mutant, a fusion protein and application thereof. A recombinant protein is obtained by screening a high-expression signal peptide and replacing a natural signal peptide in canine TPO, protein expression can be efficiently induced, mutant protein with higher expression quantity and biological activity is obtained by performing amino acid site mutation on a mature peptide cTPO in canine TPO, and the canine TPO recombinant protein and a mutant thereof are fused with truncated CTP, so that the canine TPO recombinant protein is obtained. The expression quantity and activity of the fusion protein are remarkably improved, an amino acid sequence of the fusion protein is subjected to codon optimization modification and then is expressed by using an efficient CHO expression system, and the problems that in the prior art, dog-derived thrombopoietin is short in half-life period and insufficient in stability, and heterologous protein has immunogenicity worry are solved. The canine TPO fusion protein can be effectively applied to preparation of drugs for treating canine primary or secondary thrombocytopenia.

Provided are a nucleic acid encoding thrombopoietin or a precursor thereof, and a composition and kit comprising same. Further provided is a use of the nucleic acid, the composition and the kit in treatment of thrombocytopenia.

This application provides a viral vector for hematopoietic stem cells and its application. A first aspect of this application proposes a lentiviral vector packaging system for hematopoietic stem cells, the lentiviral vector packaging system comprising a recombinant expression vector, the recombinant expression vector comprising nucleotide sequences encoding thrombopoietin and FMS-associated receptor tyrosine kinase 3 ligand. This invention, by constructing thrombopoietin and FMS-associated receptor tyrosine kinase 3 ligand onto nucleic acid molecules, thereby enabling their expression on the surface of a lentiviral vector, shows that compared to direct addition, it can effectively activate and enhance the stemness or immune activity of various cells, including hematopoietic stem cells, at lower dosages.

The present disclosure discloses a composition, method and application thereof for improving the quality of in vitro maturation of oocytes and the pregnancy rate after in vitro produced embryos transfer. The present disclosure aims at the problems of low maturation rate and poor subsequent embryo development potential caused by metabolic disorders during in vitro maturation of oocytes, and provides a composition including two or more regulators in vitamin C, L-carnitine and thrombopoietin to regulate the metabolism of oocytes, thereby greatly improving the in vitro maturation rate of oocytes and the subsequent embryo development potential. The present disclosure not only improves the efficiency of in vitro embryo production of livestock, but also provides a reference for improving the efficiency of human assisted reproductive technology. The method is simple, safe and efficient, and has great application value and broad application prospects.

Provided herein are methods, compounds, and compositions for safely reducing thrombopoietin in a cell or an individual. Such methods, compounds, and compositions maintain platelet count within a safe hemostatic range. Such methods, compounds, and compositions are useful to safely treat, prevent, or ameliorate a disease that can benefit from platelet count reduction in an individual. Such methods, compounds, and compositions are useful for treating or preventing diseases in which thrombopoietin contributes to the presence or activation of platelets contributes to and promotes disease initiation or progression, and / or adversely affects disease outcome.